DEF 14A: Globus Medical Seeks Stockholder Approval for Equity Incentive Plan Amendment
Proxy Statement
Globus Medical is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for issuance.
Summary
- Globus Medical is seeking stockholder approval to amend its 2021 Equity Incentive Plan.
- The amendment would increase the number of Class A Common Stock shares available for issuance by 1,000,000, raising the total from 8,000,000 to 9,000,000.
- The amendment would also increase the number of shares available for incentive stock options under Section 422 of the Code from 8,000,000 to 9,000,000.
- In 2023, the company awarded options for 1,897,402 shares of Class A Common Stock.
- The Board believes the amendment will enhance the company's ability to attract, motivate, and retain key personnel.
- The annual meeting of stockholders will be held on June 5, 2024.
- The board recommends voting for the election of director nominees, the approval of the amendment to the 2021 Equity Incentive Plan, the ratification of the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm, and the approval, on an advisory basis, of the compensation of the company's named executive officers.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, presenting factual information and recommendations. The sentiment is neutral to slightly positive, reflecting the company's efforts to align employee and shareholder interests.
Positives
- The proposed amendment aims to strengthen the company's ability to attract, motivate, and retain non-employee directors, employees, and consultants in a competitive environment.
- The Board believes the amendment will align the interests of key personnel with those of stockholders, promoting the company's success and enhancing its value.
Future Outlook
The Board strives to continue promoting the success and enhance the value of the Company by aligning the individual interests of non-employee directors, employees and consultants with those of stockholders.
Industry Context
Equity incentive plans are a common tool used by publicly traded companies to attract and retain talent, aligning employee interests with those of shareholders. The specific details of the plan, such as the number of shares authorized and the vesting schedules, are tailored to the company's individual circumstances and compensation philosophy.
Comparison to Industry Standards
- Globus Medical's peer group for 2024 consists of CONMED, Insulet, QuidelOrtho, The Cooper Companies, Integer, Teleflex, Dentsply Sirona, LivaNova, Alphatec Holdings, Enovis, Merit Medical Systems, Integra Lifesciences, Envista, Penumbra, and Glaukos.
- These companies are publicly-traded medical device companies that the Compensation Committee believes are the most comparable to Globus Medical.
- Comparing Globus Medical's equity compensation practices to those of its peers would provide a more comprehensive assessment of whether its proposed amendment is in line with industry standards.
Stakeholder Impact
- Approval of the amendment could positively impact employees by providing additional equity incentives.
- Approval of the amendment could positively impact shareholders by aligning employee interests with shareholder value creation.
Next Steps
- Stockholders will vote on the proposed amendment to the 2021 Equity Incentive Plan at the Annual Meeting on June 5, 2024.
Key Dates
| Date | Description |
|---|---|
| 2003 | Globus Medical's inception. |
| 2012 | Adoption of the 2012 Equity Incentive Plan. |
| 2015 | Daniel Scavilla joined Globus Medical as Chief Financial Officer. |
| 2016-05-03 | Executive employment agreement with Daniel T. Scavilla. |
| 2017-04 | Deloitte & Touche LLP has audited Globus Medical's financial statements since April 2017. |
| 2017-08 | David C. Paul transitioned into the role of Executive Chairman. |
| 2018-12 | Kelly G. Huller became the Senior Vice President, General Counsel and Corporate Secretary. |
| 2019-05 | Stephen T. Zarrilli joined the Board of Directors. |
| 2019-08 | Keith W. Pfeil joined Globus as Chief Financial Officer. |
| 2019-12 | Robert A. Douglas joined Globus Medical's Board of Directors. |
| 2020-08-05 | Executive employment agreements with Kelly G. Huller and Keith W. Pfeil. |
| 2021-06-03 | Date of the Annual Meeting of the Stockholders to be held on June 3, 2021 or such other date upon which the Company's stockholders approve the Plan. |
| 2022-04 | Daniel T. Scavilla has served as Globus Medical's President and Chief Executive Officer since April 2022. |
| 2023-09 | Daniel J. Wolterman and John A. DeFord, Ph.D. and Leslie V. Norwalk, Esq. joined the Board of Directors. |
| 2023-11 | Our Board adopted a Compensation Recoupment Policy. |
| 2023-12-31 | End of the fiscal year for which financial statements are being audited. |
| 2024-02 | Board approved an amendment to our existing 2021 Equity Incentive Plan. |
| 2024-04-01 | Date of the document. |
| 2024-04-15 | Record date for the Annual Meeting. |
| 2024-04-26 | The Notice of Internet Availability of Proxy Materials is being mailed, and the attached Proxy Statement is being made available, to our stockholders beginning on or about April 26, 2024. |
| 2024-06-04 | If you vote via the Internet or by telephone, your vote must be received by 11:59 p.m., Eastern Time, on June 4, 2024. |
| 2024-06-05 | Date of the 2024 Annual Meeting of Stockholders. |
| 2025 | Next advisory vote will occur at our 2025 Annual Meeting. |
| 2025-04-07 | Stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must comply with the additional requirements of Rule 14a-19(b) and provide notice of such solicitation by no later than April 7, 2025, although such date may change. |
| 2025-04-15 | Any stockholder wishing to bring any business including, but not limited to, the nomination of persons for election as directors, whether by inclusion of such business in our proxy materials or otherwise, before the 2025 annual meeting, must provide notice to the Company, not more than ninety (90) and not less than fifty (50) days before the annual meeting, such notice to be in writing by registered mail, return receipt requested, to our Secretary at our principal executive offices. We currently expect our 2025 annual meeting to be held on June 4, 2025, which would require that such notice be provided by no later than April 15, 2025, although such date may change. |
| 2027 | Directors elected at the Annual Meeting will hold office until the 2027 annual meeting of stockholders. |
Keywords
Equity Incentive Plan, Stock Options, Share Issuance, Executive Compensation, Globus Medical, Amendment, Stockholders
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.